ClinGuide CRISPR sgRNA for Human Therapeutics
For over 20 years Agilent has delivered customer solutions for development, manufacturing, in-process testing, raw materials analysis, drug substance release, and stability testing. Agilent develops analytical methods and RNA synthesis manufacturing processes that optimize purity and yield for your specific guide RNA.
- Oligonucleotide GMP Manufacturing
Request a Quote
Product Details
- Rigorous phase-appropriate quality systems incorporate cGMP standards and a quality-by-design approach
- Highly resolving impurity methods compatible with mass spectrometry help ensure the high purity of your CRISPR molecule
- Two cGMP facilities in Colorado are equipped for multiple products and projects to help you move seamlessly to manufacturing
- Expert team of scientists with more than 20 years of experience supporting the development of multiple clinical and commercial programs
- Work with experienced partners deeply invested in your long-term success
- Project managers coordinate cross-functional teams to gain a clear understanding of your requirements and ensure successful project completion
- Key Literature
-
Agilent ClinGuide CRISPR sgRNA for Human Therapeutics
Accelerate the clinical success of therapeutic gene editing programs.
- Flyers
- English
- 12 Oct 2023
- 1.12 MB
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- Brochures
- English
- 28 Dec 2023
- 3.19 MB
Videos
Join Agilent at TIDES Europe 2024
Hamburg Congress Center, Hamburg, Germany
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.
- Agilent to Acquire North American CDMO BIOVECTRA
- 22 Jul 2024
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 05 Dec 2022